The Plasma Protein Therapeutics Association (PPTA) represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. These therapies are used by patients worldwide to treat a variety of diseases and serious medical conditions. PPTA member companies produce approximately 80% of the plasma protein therapies in the U.S. and 60% of those manufactured in Europe.
PPTA works globally to:
PPTA Recognizes 8th Annual International Rare Disease Day +
The Plasma Protein Therapeutics Association joins more than 300 organizations in 56 countries in recognizing the 8th annual International Rare Disease Day on February 28.
Sponsored by the National Organization of Rare Disorders and Rare Diseases Europe, Rare Diseases Day seeks to raise awareness among the general public and policymakers about rare diseases, impacting lives all over the globe.Read More
PPTA Introduces New Cross Donation Check System +
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) recently launched the Cross Donation Check System (CDCS), a new electronic database designed to assist plasma centers in checking donors more efficiently and effectively.Read More
Ensuring Access to Medicines for Patients: Pharmaceutical Industry Associations Release ‘Principles for Communication of Information on Quality and Manufacturing Potential Supply Disruption’ +
(20th January 2015 – Brussels) – AESGP, EFPIA, EGA, and PPTA are pleased to announce today’s release of the joint principles for “Communication of information on quality and manufacturing potential supply disruption”. This document forms part of the industry response to the EMA (European Medicines Agency) call for voluntary and proactive action, to provide European patients with continuous access to medicines.Read More
The Source, the international magazine of the plasma protein therapeutics industry is published quarterly. Read the current issue.